About Menactra Vaccine
Age Indication
Immunogenicity
Safety
Reimbursement
Menactra Vaccine FAQs

Menactra vaccine safety is demonstrated in clinical trials in over 36,000 people and confirmed in everyday use since 2005.^1,3,4

• Adverse reactions to Menactra vaccine are generally mild and consist mainly of injection site pain, redness, and induration (all age groups); irritability, crying, drowsiness, loss of appetite, and diarrhea (infants and children); headache, fatigue, and malaise (adolescents and adults) (n=7672)¹
• Local reactions with Menactra vaccine are similar to those following tetanus and diphtheria (Td) vaccine (n=1021)¹

Important Safety Information
Indication
Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

Safety Information
The most common local and systemic adverse reactions to Menactra vaccine include injection site pain, redness, and induration (all age groups); irritability, crying, drowsiness, loss of appetite, and diarrhea (infants and children); headache, fatigue, and malaise (adolescents and adults). Other adverse reactions may occur.

Menactra vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine. Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. The decision to give Menactra vaccine should take into account the potential benefits and risks. GBS has been reported in temporal relationship following administration of Menactra vaccine. Vaccination with Menactra vaccine may not protect all individuals

Before administering Menactra vaccine, please see accompanying full Prescribing Information.